Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
- Takeda Transfers HPV Vaccine License to Kaketsuken
March 12, 2015
- Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
- AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
- Over Half of RA Patients Remained in Remission 1 Year After Stopping Enbrel: Prof. Yamanaka
March 11, 2015
- Alogliptin Demonstrates No Increased Risk of Heart Failure: Takeda
March 11, 2015
- University of Tokyo, Sanofi Collaborate for Joint Drug Discovery Research in Fields of Inflammatory Disease, Oncology
March 11, 2015
- Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
March 10, 2015
- Astellas Wins US Approval for Antifungal Agent Cresemba
March 10, 2015
- Ethical Drug Sales Down 0.1% in January: Crecon Report
March 10, 2015
- 74 Drug Makers Paid 483.1 Billion Yen to Healthcare Providers in FY2013: Jiho Tally
March 9, 2015
- Meiji Seika Pharma Commences PIII Study of Ziprasidone in Japan
March 9, 2015
- RaQualia, Nagoya Univ. Enter Joint Research Agreement for DNA Polymerase Eta Inhibitors
March 9, 2015
- US Merck, Eisai to Jointly Develop Combination Therapy of Anti-PD-1 Therapy with Anticancer Agents in US
March 9, 2015
- Eisai Aims at 120 Billion Yen Sales for Lenvima: CEO Naito
March 6, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
- Kyowa Kirin Initiates PII Study of Bardoxolone Methyl in Japan
March 6, 2015
- Opdivo Approved for Lung Cancer in US
March 6, 2015
- Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…